CDKN2A and melanoma: However, given the fact that—according to Globocan—approximately 1547 new cases of melanoma are diagnosed annually in Romania,[22] that 0.2% to 8.6% of all melanomas are represented by multiple tumors,[23] that 1% to 8% of all patients diagnosed with melanoma have at least a first-degree relative affected by the same oncological disease,[24] and that our analysis only focused on the Romanian Dobruja region, the correlation between p14, p16, and CDKN2A genetic status is considered statistically significant.